GLP-1 Side Effects & Safety 2026: Emergency vs Urgent Symptoms

- September 24, 2026

GLP-1-based medicines such as semaglutide and tirzepatide can cause gastrointestinal symptoms that are usually manageable, but they also carry warnings for uncommon yet potentially serious adverse events.

The most useful way to understand GLP-1 safety is to separate:

Emergency symptoms → seek immediate medical attention

from

Urgent symptoms → contact a healthcare professional promptly and seek same-day evaluation when appropriate

from

Common symptoms → usually monitor and manage, but discuss them if they become persistent or severe.

This distinction is important because a common side effect can occasionally become medically significant when it is severe, persistent or associated with dehydration, bleeding, severe pain, breathing problems or loss of consciousness.

This urgency framework is a practical patient-education tool, not an official FDA classification. The appropriate response depends on symptom severity, medical history and the specific GLP-1 medicine being used.

GLP-1 Safety: Emergency vs Urgent

Category	What it means	Examples
EMERGENCY	Potentially life-threatening or requiring immediate assessment	Severe allergic reaction, severe hypoglycemia with altered consciousness, collapse/severe dehydration, severe abdominal symptoms with concerning features
URGENT	Needs prompt medical assessment but may not be immediately life-threatening	Persistent vomiting, severe constipation, suspected gallbladder disease, significant abdominal pain, new/worsening vision problems
PROMPT REVIEW	Contact prescriber soon	Persistent nausea, poor nutritional intake, repeated low glucose, unexplained weakness, worsening GI intolerance
COMMON / MANAGEABLE	Frequently reported during treatment	Nausea, diarrhea, constipation, abdominal discomfort, reflux, belching, reduced appetite

1. EMERGENCY SYMPTOMS

Seek immediate medical attention

These symptoms should not be treated as routine GLP-1 side effects.

Severe allergic reaction

A serious hypersensitivity reaction can include:

Trouble breathing
Wheezing
Swelling of the lips, tongue, face or throat
Feeling faint or collapsing
Rapidly developing widespread allergic symptoms

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with semaglutide and tirzepatide. The prescribing information directs patients with serious hypersensitivity reactions to discontinue the medicine and seek medical care.

What to do

Treat suspected anaphylaxis as an emergency.

Do not wait to see whether symptoms improve on their own.

Severe hypoglycemia with confusion, seizure or loss of consciousness

GLP-1 therapies generally have a lower intrinsic risk of hypoglycemia than insulin or sulfonylureas, but the risk increases when certain glucose-lowering medicines are used together.

Severe hypoglycemia can cause:

Confusion
Abnormal behavior
Seizures
Loss of consciousness

The FDA labeling for Wegovy and Zepbound specifically addresses increased hypoglycemia risk when used with insulin or insulin secretagogues.

What to do

Severe hypoglycemia is an emergency.

Follow the person's established hypoglycemia plan and obtain emergency assistance when consciousness is impaired, a seizure occurs or the person cannot safely take glucose by mouth.

Severe dehydration, fainting or collapse

Vomiting or diarrhea can sometimes cause major fluid loss.

Warning signs include:

Fainting
Collapse
Confusion
Severe dizziness
Very little or no urination
Inability to keep fluids down
Extreme weakness

The FDA labeling warns about acute kidney injury associated with volume depletion, particularly in the setting of gastrointestinal adverse reactions.

What to do

Severe dehydration, fainting or altered mental status warrants immediate medical assessment.

Severe abdominal pain with concerning symptoms

Severe or persistent abdominal pain should never automatically be dismissed as a normal GLP-1 side effect.

Particular concern exists when severe pain is accompanied by:

Persistent vomiting
Abdominal tenderness
Back-radiating pain
Fainting or marked weakness
Abdominal distension
Inability to pass stool or gas

Acute pancreatitis is a recognized warning for GLP-1-based therapies, and FDA labeling describes severe abdominal pain, sometimes radiating to the back, with or without vomiting, as a characteristic symptom.

What to do

Severe abdominal pain requires urgent assessment and may require emergency care, particularly when symptoms are intense, persistent or accompanied by vomiting, collapse or other concerning signs.

Severe abdominal distension with vomiting or inability to pass stool or gas

The FDA updated Zepbound labeling in 2026 to include postmarketing reports of:

Intestinal obstruction
Severe constipation
Fecal impaction

under severe gastrointestinal adverse reactions.

Symptoms such as severe abdominal pain, marked distension, vomiting and inability to pass stool or gas can be concerning for an obstruction.

What to do

Seek urgent medical assessment; emergency care may be necessary when symptoms are severe or rapidly worsening.

2. URGENT SYMPTOMS

Contact a healthcare professional promptly

These symptoms may not always be immediately life-threatening, but they should not simply be ignored.

Persistent vomiting

Occasional nausea or vomiting can occur, especially during treatment initiation or dose escalation.

It becomes more concerning when:

Vomiting continues repeatedly
You cannot keep fluids down
You cannot eat adequately
You become dizzy or weak
Urination decreases
You are losing weight very rapidly

Severe gastrointestinal adverse reactions are recognized in current semaglutide and tirzepatide labeling.

Action

Contact your healthcare professional promptly.

If severe dehydration, fainting, confusion or collapse develops, treat it as an emergency.

Severe or persistent constipation

Constipation is common with GLP-1 treatment.

It becomes urgent when it is:

Severe
Persistent
Painful
Associated with abdominal swelling
Associated with vomiting
Associated with inability to pass stool or gas

The 2026 Zepbound labeling specifically added postmarketing reports of intestinal obstruction and severe constipation including fecal impaction.

Action

Seek prompt medical assessment.

Severe abdominal distension, vomiting or collapse can move this from an urgent problem to an emergency.

Possible gallbladder disease

Acute gallbladder disease is a recognized risk during GLP-1-based weight-loss treatment.

Warning symptoms can include:

Significant upper abdominal pain
Right-upper abdominal pain
Pain associated with meals
Nausea or vomiting
Fever
Yellowing of the skin or eyes

FDA labeling for semaglutide and tirzepatide warns about acute gallbladder disease and also notes that rapid or substantial weight loss can increase gallbladder risk.

Action

Contact a healthcare professional promptly for evaluation.

Severe pain, fainting or signs of a serious systemic illness warrant emergency evaluation.

New or worsening vision changes

People with diabetes, particularly those with diabetic retinopathy, may require additional monitoring during major improvements in glucose control.

Current prescribing information includes a warning concerning diabetic retinopathy complications.

Action

Prompt medical or ophthalmologic assessment is appropriate for significant or rapidly worsening vision symptoms.

Sudden major vision loss is an emergency regardless of the suspected cause.

3. PROMPT REVIEW: CONTACT YOUR PRESCRIBER SOON

These symptoms may not require an emergency department, but they deserve attention when persistent.

Persistent nausea

Nausea is one of the most common GLP-1 adverse effects.

The concern increases when nausea causes:

Poor food intake
Inadequate protein intake
Dehydration
Weakness
Difficulty taking other essential medications

Excessive appetite suppression

Reduced appetite is an intended effect of GLP-1 therapy.

However:

Less hungry is different from unable to eat enough.

A person who can barely eat or drink may develop inadequate protein, micronutrient and fluid intake.

Persistent diarrhea

Diarrhea becomes clinically important when it causes:

Dehydration
Dizziness
Reduced urination
Weakness
Significant weight loss

Persistent abdominal discomfort, reflux or bloating

Mild GI symptoms may be manageable.

Persistent symptoms that interfere with eating, sleep or daily activities warrant treatment review.

Repeated low blood glucose

Repeated hypoglycemia is particularly important in people also taking insulin or sulfonylureas.

Medication doses may need adjustment by the treating clinician.

Unexplained weakness or declining physical function

New weakness should not automatically be attributed to “normal weight loss.”

Possible contributors include:

Inadequate calories
Insufficient protein
Dehydration
Lean-mass loss
Electrolyte abnormalities
Anemia
Medication interactions
An unrelated medical condition

This is particularly important in older adults and people at risk of sarcopenia.

4. COMMON GLP-1 SIDE EFFECTS

These are frequently reported and are often manageable.

Nausea

Nausea is particularly common during treatment initiation and dose escalation.

Diarrhea

Usually manageable, but persistent diarrhea can lead to dehydration.

Constipation

Common and often manageable, but severe or progressive constipation requires assessment.

Abdominal discomfort

Mild abdominal symptoms can occur as gastrointestinal motility and appetite change.

Belching and reflux

Changes in gastric emptying and meal size can contribute.

Early fullness

Reduced appetite and earlier satiety are expected pharmacological effects.

Fatigue

Fatigue may occur, but persistent or severe fatigue should not automatically be blamed on GLP-1 therapy.

5. Important Risks Before Starting Treatment

Some safety issues are primarily about patient selection and monitoring, rather than emergency symptoms.

Personal or family history of medullary thyroid carcinoma

Semaglutide and tirzepatide carry boxed warnings concerning thyroid C-cell tumors based on findings in rodents.

The human relevance of these findings has not been established.

Wegovy and Zepbound are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

This is primarily a pre-treatment screening issue.

Planned surgery, anesthesia or deep sedation

GLP-1 medicines delay gastric emptying.

FDA prescribing information includes a warning concerning pulmonary aspiration during general anesthesia or deep sedation.

Patients scheduled for surgery or procedures should tell their anesthesia and procedural team that they use a GLP-1-based medicine.

Medication management before surgery should be individualized rather than decided independently by the patient.

Severe gastrointestinal disease

Patients with substantial pre-existing gastrointestinal disease should discuss treatment carefully with their healthcare professional.

The Zepbound labeling states that the medicine has not been studied in patients with severe gastrointestinal disease and is not recommended in such patients.

Kidney disease

GLP-1 therapy should not simply be described as inherently “kidney toxic.”

A major concern is volume depletion, particularly when vomiting or diarrhea causes dehydration.

People with kidney disease may therefore require greater caution when significant gastrointestinal symptoms develop.

Diabetic retinopathy

Patients with diabetes and established retinopathy should discuss appropriate monitoring with their healthcare professional.

The presence of diabetic retinopathy does not automatically mean GLP-1 treatment is inappropriate.

6. What the FDA Says About Suicidal Thoughts and GLP-1 Drugs

This topic should be kept up to date because the regulatory position changed in 2026.

On January 13, 2026, the FDA requested removal of suicidal behavior and ideation warnings from the labeling of Saxenda, Wegovy and Zepbound after a comprehensive evaluation found no increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonists. The FDA reviewed 91 placebo-controlled trials involving 107,910 patients and also conducted a large Sentinel analysis.

Therefore, an up-to-date GLP-1 safety guide should not describe suicidal behavior as an established GLP-1-specific adverse effect.

However, any person experiencing suicidal thoughts or behavior requires immediate appropriate mental-health support regardless of the suspected cause.

7. When Is a GLP-1 Symptom “Normal”?

A useful distinction is:

Common and mild

Mild nausea
Mild constipation
Mild diarrhea
Mild bloating
Reduced appetite
Temporary fullness

Increasingly concerning

Symptoms are persistent
Symptoms interfere with eating
Symptoms interfere with hydration
Symptoms cause weakness
Symptoms become progressively worse

Potentially dangerous

Severe pain
Severe dehydration
Loss of consciousness
Breathing difficulty
Severe allergic symptoms
Severe hypoglycemia
Concerning abdominal obstruction symptoms

The severity and clinical context matter more than simply whether a symptom appears on a medication's side-effect list.

8. Emergency vs Urgent: The Simple Rule

EMERGENCY

Seek immediate medical attention for:

Difficulty breathing or swelling of the face, lips, tongue or throat

Severe hypoglycemia with confusion, seizure or loss of consciousness

Severe dehydration with fainting, collapse or altered mental status

Severe or rapidly worsening abdominal symptoms, particularly with vomiting, collapse or other concerning features

Sudden major vision loss or another acute medical emergency

URGENT

Contact a healthcare professional promptly for:

Persistent vomiting

Severe or persistent constipation

Significant abdominal pain

Possible gallbladder symptoms

New or worsening vision symptoms

Repeated hypoglycemia

Inability to maintain adequate food or fluid intake

Significant weakness or declining physical function

COMMON / MANAGEABLE

Monitor and discuss at routine follow-up when appropriate:

Nausea

Mild constipation

Mild diarrhea

Mild abdominal discomfort

Belching or reflux

Reduced appetite

Mild transient fatigue

The categories can change as symptoms evolve.

A patient who initially has mild constipation but later develops severe abdominal pain, vomiting and abdominal distension is no longer in the “common/manageable” category.

9. GLP-1 Safety and Dose Escalation

Many gastrointestinal adverse effects become more noticeable during dose escalation.

This is why dose titration is an important part of GLP-1 safety.

The practical goal is not:

Reach the highest dose as quickly as possible.

It is:

Reach an effective and tolerable dose appropriate for the individual patient.

Persistent side effects should be discussed with the prescriber rather than automatically tolerated in the belief that more severe symptoms mean better weight loss.

10. GLP-1 Safety and Weight Loss Speed

Rapid weight loss can be clinically beneficial, but very low food intake can create nutritional problems.

A person losing substantial weight should pay attention to:

Protein intake
Hydration
Strength
Exercise capacity
Nutritional adequacy
Micronutrients
Symptoms of excessive GI intolerance

This connects directly with the OneDayMD guide:

GLP-1 Muscle Loss: How to Preserve Lean Mass, Strength & Metabolic Health

The objective is not simply maximum weight reduction.

It is high-quality weight loss while preserving physical function and nutritional health.

11. GLP-1 Safety and Compounded Products

FDA-approved products and compounded preparations should not be treated as interchangeable.

The regulatory status, manufacturing controls, formulation, concentration, labeling and dosing instructions can differ.

This makes a dedicated review of compounded semaglutide and compounded tirzepatide an important safety topic.

Patients should verify exactly what product they are receiving and follow appropriate prescribing and dispensing instructions.

12. Risk Factors That May Deserve Extra Attention

Additional caution may be appropriate for people with:

Older age
Frailty
Pre-existing sarcopenia
Significant kidney disease
Severe gastrointestinal disease
Diabetic retinopathy
Previous gallbladder disease
Concomitant insulin or sulfonylurea therapy
Major nutritional restriction
Planned surgery or deep sedation

These factors do not automatically make GLP-1 therapy inappropriate.

They indicate situations where individualized clinical management matters more.

13. A Patient-Friendly GLP-1 Safety Checklist

Before starting

Discuss:

Medical history

Current medications

Diabetes treatment

Kidney function when relevant

Eye disease

Gallbladder history

GI disorders

MTC/MEN2 history

Planned surgery or anesthesia

During treatment

Monitor:

GI symptoms

Hydration

Food intake

Weight trajectory

Strength and physical function

Blood glucose when relevant

Vision when clinically indicated

Medication interactions

Know your red flags

Emergency

Breathing difficulty, facial/throat swelling, severe hypoglycemia with impaired consciousness, collapse or severe dehydration, or severe rapidly worsening abdominal symptoms.

Urgent

Persistent vomiting, severe constipation, significant abdominal pain, possible gallbladder disease, significant vision changes, repeated hypoglycemia or inability to maintain hydration/nutrition.

14. Evidence Hierarchy for GLP-1 Safety

Not every safety claim deserves equal weight.

Evidence	Example	Interpretation
E5 — Regulatory	FDA labeling and safety communications	Highest practical authority for recognized warnings and contraindications
E4 — Randomized trials	Phase 3 GLP-1 trials	Controlled adverse-event data
E3 — Observational studies	Claims/EHR analyses	Real-world associations and comparative safety
E2 — Pharmacovigilance	Postmarketing reports	Safety signals requiring investigation
E1 — Case reports	Individual reports	Useful for unusual events but poor for estimating incidence

A case report can identify a signal.

It cannot by itself prove that a medication caused the event or establish how frequently it occurs.

15. Why “GLP-1 Side Effects” Is Too Broad

Search results often collapse everything into a single list.

That is not how patients actually experience medication safety.

A much more useful framework is:

What is common?

What should I monitor?

When should I call my doctor?

When should I seek urgent care?

When is this an emergency?

This is also the structure OneDayMD should use for its broader GLP-1 evidence library.

Bottom Line

GLP-1 medicines are associated with many common gastrointestinal side effects, while serious complications are less common but clinically important.

The critical distinction is emergency versus urgent versus common.

EMERGENCY

Potentially life-threatening symptoms such as severe allergic reactions, severe hypoglycemia with altered consciousness, collapse/severe dehydration, or severe abdominal symptoms with concerning features require immediate medical attention.

URGENT

Persistent vomiting, severe constipation, significant abdominal pain, possible gallbladder disease, major vision changes or repeated hypoglycemia warrant prompt medical assessment.

COMMON

Nausea, mild constipation, diarrhea, abdominal discomfort, belching, reflux and reduced appetite are frequently reported and are often manageable.

The safest approach is not to ignore symptoms and not to panic over every symptom.

It is to understand which symptoms are expected, which require escalation, and which require immediate medical care.

Primary sources

FDA — Wegovy prescribing information
FDA — Zepbound 2026 labeling update
FDA — GLP-1 suicidal behavior and ideation safety update, January 13, 2026
Kidney and Gastro Issues Linked to Ozempic. OneDayMD
Booming Demand for Obesity Pill to Solve Junk Food Problem. AestheticsAdvisor
Ozempic Use Now Linked to 'Deflated' Breasts. AestheticsAdvisor
Thyroid Cancer Concerns Raised Regarding Active Ingredient in Popular Drugs Ozempic and Wegovy. OneDayMD
Over 200 Cases of Suicidal Thoughts After Taking Weight Loss Drugs: Reuters Analysis. Reuters
MHRA updates guidance for semaglutide prescribers and patients on NAION risk. February 5, 2026. GOV.UK
Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss. September 2026. The Wall Street Journal.
Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss: What the Evidence Shows. September 2026. OneDayMD

Related OneDayMD evidence hub: GLP-1 Clinical Trials & Studies

Medical disclaimer

This article is for educational purposes and is not a substitute for individualized medical advice. GLP-1 medicines differ in their approved indications, doses, contraindications and labeling. Patients should consult the prescribing information for their specific medicine and contact their healthcare professional about significant or persistent symptoms. In an emergency, seek emergency medical care rather than relying on an online resource.